Hypera receives Anvisa approval for semaglutide pen, removing key regulatory barrier

Brazilian health regulator Anvisa has approved Hypera's semaglutide pen, clearing a significant regulatory hurdle for the company's entry into the GLP-1 market. Analysts anticipate this development will trigger upward revisions to revenue and profit forecasts, though the competitive landscape for weight-loss drugs remains intense.